Announcements

AbbVie Inc. filed a Form 8-K with the SEC on September 3, 2026, disclosing under Item 7.01 (Regulation FD) the completion of its acquisition of Apogee Therapeutics, Inc., as announced in an attached press release dated the same day.

Apogee Therapeutics, Inc. filed a Form 8-K on September 3, 2026, reporting the completion of its merger with a wholly owned subsidiary of AbbVie Inc., making Apogee an indirect wholly owned subsidiary of AbbVie at a total equity value of approximately $10.9 billion.

CarGurus, Inc. filed an 8-K with the SEC on September 3, 2026, disclosing the appointment of Matthew Mandel as Chief Financial Officer, principal financial officer, and principal accounting officer, effective October 19, 2026.

MediaAlpha, Inc. filed a Form 8-K on September 3, 2026, reporting the appointment of Tigran Sinanyan as Chief Financial Officer and Treasurer, effective October 1, 2026, and the planned departure of current CFO Patrick Thompson.

Dick's Sporting Goods, Inc. filed a Form 10-Q with the Securities and Exchange Commission for the quarterly period ended August 1, 2026, reporting net sales, earnings, and balance sheet data for both the 13-week and 26-week periods ended on that date.

John Wiley & Sons, Inc. filed a Current Report on Form 8-K on September 3, 2026, disclosing the company's financial results for the first quarter of fiscal year 2027 via a press release and related earnings conference call presentation materials.

Summit Therapeutics Inc. filed a Form 8-K on September 3, 2026, reporting that its partner Akeso Inc. announced positive overall survival results from the Phase III HARMONi-2 study evaluating ivonescimab monotherapy versus pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung …